Homma 2003.

Methods	8‐week washout period 24‐week before and after trial
Participants	30 men and women with non familial type 2 hyperlipoproteinaemia exclusion criteria: familial hypercholesterolaemia and familial combined hyperlipoproteinaemia TG > 350 mg/dL (3.95 mmol/L) and those treated with probucol, diabetes mellitus, CHD, or cerebrovascular disease Fluvastatin 20 mg/day baseline TC : 7.76 mmol/L (300 mg/dL) Fluvastatin 20 mg/day baseline LDL‐C : 5.25 mmol/L (203 mg/dL) Fluvastatin 20 mg/day baseline HDL‐C : 1.66 mmol/L (64 mg/dL) Fluvastatin 20 mg/day baseline triglycerides: 1.9 mmol/L (168 mg/dL)
Interventions	Fluvastatin 20 mg/day for 12 weeks Fluvastatin 40 mg/day 12‐24 weeks
Outcomes	per cent change from baseline at 12 weeks of serum TC, LDL‐C, HDL‐C, and triglycerides
Source of Funding	unknown
Notes	Fluvastatin 40 mg/day 12‐24 weeks was not analysed SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before and after design
Allocation concealment (selection bias)	High risk	Controlled before and after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	High risk	No comparison possible
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding was not reported